2. UroToday Home
  3. Conference Highlights
  4. AUA 2026
  5. AUA 2026 Press Releases

AUA 2026

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Reno, Nevada (UroToday.com) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company’s phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer.

Presentation Details:

Aglatimagene – Localized Prostate Cancer

  • Abstract Title: Extended follow-up shows accumulating benefit for patients treated with CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) in men with localized prostate cancer: update from PrTK03 randomized phase 3 clinical trial
  • Presentation Type: Plenary
  • Presenter: Mark G. Garzotto, M.D., Professor of Urology and Radiation Medicine, Oregon Health & Science University, Chief, Urology Section, Portland VA Medical Center
  • Session Title: P2s: Practice-changing, Paradigm-shifting Clinical Trials in Urology
  • Session Date/Time: Friday, May 15, 2026; 11:30 AM - 11:40 AM ET
  • Location: Hall D, Walter E. Washington Convention Center, Washington, D.C.
Full abstracts will be released by AUA on date and time of presentation. Details from the presentation will be available following the event on the Candel website at https://www.candeltx.com/media/. 

Source: Candel Therapeutics, Inc. (2026). Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting [Press release]. https://www.biospace.com/press-releases/candel-therapeutics-to-present-new-data-after-extended-follow-up-from-randomized-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-american-urological-association-2026-annual-meeting.